In primary CLL cells with an active Lyn-HS1 axis, the treatment with the Lyn inhibitor Dasatinib results in a reduction of the Lyn activity, HS1 phosphorylation and F-actin polymerization (18). The gene discussed is LYN; the disease is B-cell chronic lymphocytic leukemia.